{"entity":{"id":"nct04395677","kind":"trial","name":"A Study of AB-106 in Subjects With Advanced NSCLC Harboring ROS1 Fusion Gene","aka":[],"tldr":"A phase 2 trial of AB-106 in non-small-cell lung cancer, run by Nuvation Bio Inc., active and no longer recruiting.","summary":"A Study of AB-106 in Subjects With Advanced NSCLC Harboring ROS1 Fusion Gene is a phase 2 interventional study registered as NCT04395677 by Nuvation Bio Inc., with 173 participants enrolled, started 2020-07-07 and due to reach its primary completion in 2024-06-07. Interventions recorded: AB-106.","status":"active","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT04395677","url":"https://clinicaltrials.gov/study/NCT04395677"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["nsclc","ros1-positive-nsclc"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":["nuvation-bio"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":["paper-nct04395677-j-clin-oncol-2024","paper-nct04395677-j-clin-oncol-2026-update"],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT04395677","phase":"2","setting":"A Multicenter, Open Label, Single Arm Phase 2 Study of AB-106 in the Treatment of Locally Advanced and Metastatic NSCLC","sponsor":"Nuvation Bio Inc.","started":"2020-07-07","startedType":"actual","enrolled":173,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct04395677/","neighbours":{"cancer":[{"id":"nsclc","kind":"cancer","name":"Non-small-cell lung cancer","route":"/cancers/nsclc/"},{"id":"ros1-positive-nsclc","kind":"cancer","name":"ROS1-positive non-small-cell lung cancer","route":"/cancers/ros1-positive-nsclc/"}],"company":[{"id":"nuvation-bio","kind":"company","name":"Nuvation Bio","route":"/companies/nuvation-bio/"}],"paper":[{"id":"paper-nct04395677-j-clin-oncol-2024","kind":"paper","name":"Efficacy and Safety of Taletrectinib in Chinese Patients With ROS1+ Non-Small Cell Lung Cancer: The Phase II TRUST-I Study","route":"/key-papers/paper-nct04395677-j-clin-oncol-2024/"},{"id":"paper-nct04395677-j-clin-oncol-2026-update","kind":"paper","name":"Long-Term Efficacy and Safety of Taletrectinib in Patients With ROS1 + Non-Small Cell Lung Cancer: Results From the Phase II TRUST-I Study","route":"/key-papers/paper-nct04395677-j-clin-oncol-2026-update/"}]}}